OPHD 002
Latest Information Update: 22 Nov 2006
At a glance
- Originator Promega Corporation
- Class
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Inflammatory bowel diseases
Most Recent Events
- 08 Jun 2000 Ophidian has suspended research and product development operations
- 08 Jun 2000 Suspended-Preclinical for Inflammatory bowel disease in USA (PO)
- 22 Jul 1999 Preclinical development for Inflammatory bowel disease in USA (PO)